Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with treatment-naïve NSCLC harboring L858R or del19 EGFR mutation who are suspected to have poor response upon single-agent TKI treatment.

Trial Details

NCT ID

NCT05281406

Phase

PHASE2

Sponsor

Goethe University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Osimertinib
Pemetrexed
Cisplatin
Carboplatin

Locations (sample)

Berlin, Germany|52.52437,13.41053
Cologne, Germany|50.93333,6.95
Dresden, Germany|51.05089,13.73832
Essen, Germany|51.45657,7.01228
Frankfurt, Germany|49.68333,10.53333

Key Eligibility Criteria

Pre-Screening Phase
Provision of written informed consent for the pre-screening phase.
Age ≥ 18 years
Histologically confirmed stage IIIB or IV NSCLC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →